Choovuthayakorn Janejit, Khunsongkiet Preeyanuch, Patikulsila Direk, Watanachai Nawat, Kunavisarut Paradee, Chaikitmongkol Voraporn, Ittipunkul Nimitr
Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Thailand.
J Ophthalmol. 2019 Mar 17;2019:9481902. doi: 10.1155/2019/9481902. eCollection 2019.
To report characteristics and visual results in patients with PDR-associated complications following pars plana vitrectomy (PPV) in a tertiary center over an eight-year period.
Medical records of diabetic retinopathy patients receiving PPV between January 2007 and December 2014 for PDR-related complications were reviewed.
A total of 890 consecutive PDR patients were included in the study. PPVs were performed for tractional retinal detachment (36.6%), persistent vitreous hemorrhage (VH) (35.4%), combined tractional and rhegmatogenous retinal detachment (14.5%), and vitreoretinal abnormalities (13.5%), respectively. Preoperative intravitreal bevacizumab injection (IVB) within two weeks prior to PPV and 23G vitrectomy systems was found to decrease the risk for intraoperative retinal break development (=0.045 and =0.015, respectively). The incidence of early dense postoperative VH decreased significantly with the administration of preoperative or intraoperative IVB at the end of PPV. Postoperative visual results significantly correlated with the initial visual acuity level, intraoperative retinal break development, and retained silicone oil tamponade at the final visit ( < 0.001, =0.040, and =0.044, respectively). Administration of adjuvant IVB either before or at the end of PPV had no significant association with the final visual outcomes.
This study reported an improvement in visual acuity in nearly half of patients receiving PPV for PDR-associated complications in a limited resource center. The incidence of intraoperative retinal break and early postoperative VH decreased significantly with the application of IVB injections. Poor final visual outcomes were related to the lower initial visual acuity levels, intraoperative retinal breaks, and postoperative retained silicone oil.
报告在一家三级中心八年期间接受玻璃体切割术(PPV)治疗增殖性糖尿病视网膜病变(PDR)相关并发症患者的特征及视力结果。
回顾2007年1月至2014年12月期间因PDR相关并发症接受PPV的糖尿病视网膜病变患者的病历。
该研究共纳入890例连续的PDR患者。PPV分别用于治疗牵拉性视网膜脱离(36.6%)、持续性玻璃体积血(VH)(35.4%)、牵拉性和孔源性视网膜脱离合并症(14.5%)以及玻璃体视网膜异常(13.5%)。发现在PPV前两周内进行术前玻璃体内注射贝伐单抗(IVB)以及使用23G玻璃体切割系统可降低术中视网膜裂孔形成的风险(分别为=0.045和=0.015)。在PPV结束时给予术前或术中IVB,术后早期严重VH的发生率显著降低。术后视力结果与初始视力水平、术中视网膜裂孔形成以及末次随访时硅油填充情况显著相关(分别为<0.001、=0.040和=0.044)。在PPV之前或结束时给予辅助性IVB与最终视力结果无显著关联。
本研究报告了在资源有限的中心,近一半接受PPV治疗PDR相关并发症的患者视力有所改善。IVB注射的应用显著降低了术中视网膜裂孔和术后早期VH的发生率。最终视力不佳与较低的初始视力水平、术中视网膜裂孔以及术后硅油残留有关。